NCT00035087已完成2 期
An Open-Label Phase IIa Trial Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients With Advanced Colorectal Cancer
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 62
- 试验地点
- 2
- 主要终点
- Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)
研究概览
简要总结
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause colorectal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)
次要结局
- Time to progression
- Overall survival
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal CancerOvarian NeoplasmsPeritoneal NeoplasmsFallopian Tube NeoplasmsNCT00035100Novartis Pharmaceuticals54
已完成
2 期
EPO906 Therapy in Patients With Prostate CancerProstatic NeoplasmsNCT00035113Novartis Pharmaceuticals48
已完成
2 期
EPO906 Therapy in Patients With Advanced MelanomaMelanomaNCT00035165Novartis Pharmaceuticals51
已完成
2 期
EPO906 Therapy in Patients With Advanced Kidney CancerKidney NeoplasmsNCT00035243Novartis Pharmaceuticals53
已完成
2 期
EPO906 Therapy in Patients With Advanced Breast CancerBreast NeoplasmsNCT00035126Novartis Pharmaceuticals46